Decipher Labs Share Price

Decipher Labs Ltd. (formerly known as Combat Drugs Ltd) was incorporated as a Private Limited Company in September, 1986 and was converted into a Public Limited Company in Jun.92. The company was promoted by Suchit Mohan Lal and Ajay Karan. The Company is a professionally managed, well established, diversified Public Limited Company, engaged in the Manufacture Marketing of Pharmaceuticals and allied products and services and providing Services and key Solutions in Information Technology Industry. Since inception, the Company has been manufacturing marketing its branded formulations and custom manufacturing for various companies besides supplies of various Bulk drugs, chemicals and Finished Formulations. During the years of operations, it has garnered a reputation as a quality provider in the Pharmaceutical industry and the Products marketed by the Company have been well accepted by the Trade and Medical Fraternity across India.The Company also diversified interest in the field on Information Technology and has developed a name for itself as a key solution provider in the field of associated technologies. It expanded by reviving the Information Technology wing and started dealing and reviving its associations into the Information Technology Industry. To increase presence in the Information Technology segment, the Company acquired Decipher Software Solutions LLC in USA to add good volumes to the overall turnover and Profits of the Company. The Company came out with a public issue of 23.23 lac equity shares at par aggregating Rs 2.32 cr in Nov.94. The proceeds of the issue were utilised to partfinance a Rs 3.25cr project to expand the existing manufacturing facilities for pharmaceutical formulations and to diversify into the manufacture of sterile powder injectables.CDL started commercial production in Jul.87 on a loanlicence basis. The company acquired a fullfledged manufacturing unit located at Balanagar, Hyderabad, on lease from Fairchild Laboratories and commenced commercial production in Aug.88. In Jul.92 the manufacturing activities were shifted to the present leased premises at Kushaiguda, Hyderabad. In this unit various pharmaceutical formulations such as tablets, capsules and liquids are being manufactured. The product range of CDL comprises vital antibacterial drugs, antibiotic drugs, antiinflammatory drugs, haematenic drugs and protein tonic. CDL has developed inhouse technology for the manufacture of dispersible and sustained release formulations. The company is exploring the possibilities of exporting its products to Nigeria and West Indies. During the year 199596, the expansion programme undertaken by the company was successfully completed and the unit at Yellampet has become operational.During 199697, the company has expanded its operations to new areas. It has expanded its product range by introduction of Liquid Orals. The product HB 2 has been well accepted in the market. The company has also filled its application for obtaining the (c)GMP and WHO GMP Certificate.

Decipher Labs reported a Q2 FY2025–2026 revenue of ₹2.92 crore, down -34.1% YoY, with net profit increased 202.4% to ₹-3.43 crore. For the full year FY2025–2026, revenue reached ₹23.93 crore and profit touched at ₹-5.08 crore. As of Jun '25, Decipher Labs’s market capitalisation stood at ₹10.81 crores. Shareholding as of Jun '25 shows promoters holding 16.4%, with FIIs at 83.6%, DIIs at %, and public at %.

As of 19 Aug, 2025, Decipher Labs share price is ₹10.7. The stock opened at ₹10.6 and had closed at ₹10.5 the previous day. During today’s trading session, Decipher Labs share price moved between ₹10.44 and ₹11.02, with an average price for the day of ₹10.73. Over the last 52 weeks, the stock has recorded a low of ₹9.61 and a high of ₹18.90. In terms of performance, Decipher Labs share price has declined by 10.8% over the past six months and has declined by 40.49% over the last year.